Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.90 |
| ▸ | RAF1 | P04049 | 10/20 | 0.90 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.73 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.73 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.73 |
| ▸ | GCGR | P47871 | 3/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643418 | 0.95 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL29355176 | 0.95 | BRAF (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| Bromide SCHEMBL7648283 | 0.93 | BRAF (0.95) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL7648286 | 0.90 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL15075633 | 0.89 | BRAF (0.91) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL14689935 | 0.85 | RAF1 (0.67) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL2649589 | 0.84 | MAPK13 (0.90) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL28403334 | 0.84 | MAPK13 (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL6469877 | 0.82 | MAPK14 (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 | |
| SCHEMBL5921859 | 0.82 | MAPK13 (1.00) | BRAFRAF1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | BRAF 2682/4885RAF1 737/4885MAPK13 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.